AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27119581 — intervention group
Group type: COMPARATOR
Intervention: Softgel capsule vs Oral solution
Number of subjects: 0
Study 27119581 — intervention group
Group type: COMPARATOR
Intervention: Softgel capsule vs Tablet
Number of subjects: 0
Study 27119581 — intervention group
Group type: EXPERIMENTAL
Intervention: Softgel capsule
Number of subjects: 0
Study 24884854 — intervention group
Group type: EXPERIMENTAL
Intervention: TBL + LBL (Group A, 41 students)
Number of subjects: 127
Study 24884854 — intervention group
Group type: COMPARATOR
Intervention: LBL (Group B, 43 students)
Number of subjects: 127
Study 24884854 — intervention group
Group type: COMPARATOR
Intervention: TBL (Group C, 43 students)
Number of subjects: 127
Study 22367274 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy by a trained nurse for 10 weeks
Number of subjects: 27
Study 22367274 — intervention group
Group type: COMPARATOR
Intervention: Telephone calls only for 10 weeks
Number of subjects: 27
Study 20139154 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. chemotherapy
Number of subjects: 89
Study 18368792 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric metaplasia in the duodenum
Number of subjects: 124
Study 15839930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy plus intracorporeal lithotripsy (ULT)
Number of subjects: 31
Study 15839930 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 31
Study 15839930 — intervention group
Group type: COMPARATOR
Intervention: ESWL (second treatment)
Number of subjects: 31
Study 15839930 — intervention group
Group type: EXPERIMENTAL
Intervention: ULT
Number of subjects: 31
Study 15839930 — intervention group
Group type: EXPERIMENTAL
Intervention: ULT and ESWL
Number of subjects: 31
Study 12401756 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 24
Study 12401756 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 24
Study 10430693 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid videosigmoidoscope
Number of subjects: 58
Study 10430693 — intervention group
Group type: COMPARATOR
Intervention: Conventional sigmoidoscope
Number of subjects: 58
Study 7749710 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic tension-free mesh repair
Number of subjects: 242
Study 7749710 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein tension-free mesh repair
Number of subjects: 242
Study 2193278 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine (lidocaine) aerosol 10%
Number of subjects: 12
Study 2193278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Number of subjects: 12
Study 2193278 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine hydrochloride 5%
Number of subjects: 12
Study 2193278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6865429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6865429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol doses
Number of subjects: 40
Study 6865429 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol doses
Number of subjects: 40
Study 30819926 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-melphalan-prednisone (KMP)
Number of subjects: 955
Study 30819926 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 955
Study 29800093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral Valve Repair
Number of subjects: 1122
Study 29800093 — intervention group
Group type: COMPARATOR
Intervention: Mitral Valve Replacement
Number of subjects: 1122
Study 27380104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus-intercostal plane block and intermediate cervical plexus blocks (block group, n = 11)
Number of subjects: 22
Study 27380104 — intervention group
Group type: COMPARATOR
Intervention: No block (control group, n = 11)
Number of subjects: 22
Study 24147809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 67
Study 22865490 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg tramadol and 100 mg dexketoprofen trometamol
Number of subjects: 40
Study 22865490 — intervention group
Group type: COMPARATOR
Intervention: 600 mg tramadol with 100 ml 0.9% normal saline
Number of subjects: 40
Study 19937984 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal saddle block (1.0 ml 0.5 per cent hyperbaric bupivacaine)
Number of subjects: 201
Study 19937984 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA) with propofol and fentanyl
Number of subjects: 201
Study 19937984 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal saddle block
Number of subjects: 201
Study 19937984 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 201
Study 17991935 — intervention group
Group type: EXPERIMENTAL
Intervention: Care by general practitioners specially trained in management of hypertension
Number of subjects: 200
Study 17991935 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 15800328 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral hydration with 1,000 mL administered over 4 hours for 2 days
Number of subjects: 49
Study 15800328 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 100 mL normal saline administered over 4 hours for 2 days
Number of subjects: 49
Study 15800328 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral hydration
Number of subjects: 49
Study 15800328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 11921156 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg per day for the first four weeks, then 10 mg per day thereafter)
Number of subjects: 30
Study 11921156 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 30
Study 11921156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9617020 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole and secnidazole
Number of subjects: 40
Study 9617020 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone, nystatin, and metronidazole (vaginal ovules)
Number of subjects: 40
Study 8580047 — intervention group
Group type: EXPERIMENTAL
Intervention: Word processing intervention
Number of subjects: 14
Study 2572628 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 0
Study 334478 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg flurbiprofen daily
Number of subjects: 30
Study 334478 — intervention group
Group type: COMPARATOR
Intervention: 75 mg indomethacin daily
Number of subjects: 30
Study 26142337 — intervention group
Group type: EXPERIMENTAL
Intervention: FRG + GP chemotherapy
Number of subjects: 60
Study 26142337 — intervention group
Group type: COMPARATOR
Intervention: GP chemotherapy alone
Number of subjects: 60
Study 25534295 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-pegylated liposomal doxorubicin (CD)
Number of subjects: 259
Study 25534295 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (CP)
Number of subjects: 259
Study 23876971 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 120
Study 23876971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21399960 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic (IT) eccentric contractions
Number of subjects: 17
Study 21399960 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic (IK) eccentric contractions
Number of subjects: 17
Study 21399960 — intervention group
Group type: COMPARATOR
Intervention: Both IT and IK modes
Number of subjects: 17
Study 19760931 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy
Number of subjects: 45
Study 19760931 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler guided haemorrhoidal artery ligation
Number of subjects: 45
Study 19760931 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy
Number of subjects: 45
Study 17383302 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CCR)
Number of subjects: 104
Study 17383302 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 104
Study 15365928 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block with 7 mL of lidocaine 2% and repeated doses of 5 mL of lidocaine 2% during the operation.
Number of subjects: 32
Study 15365928 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository (NSAID)
Number of subjects: 32
Study 15365928 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 11136300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil 80 mg
Number of subjects: 16
Study 11136300 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 16
Study 8781009 — intervention group
Group type: EXPERIMENTAL
Intervention: DARE intervention
Number of subjects: 31
Study 8781009 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 31
Study 1333267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 6-thioguanine (6-TG) at 55 mg/m2 administered over 30 minutes for 5 consecutive days, repeated every 35 days.
Number of subjects: 95
Study 1333267 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m2 on day 1), 5-fluorouracil (800 mg/m2/day as continuous intravenous infusion over 5 days), and oral leucovorin (100 mg every 4 hours during the entire duration of cisplatin and 5-FU infusions), repeated every three weeks.
Number of subjects: 95
Study 3881497 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 30
Study 3881497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 30
Study 31340012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1200 IU/d)
Number of subjects: 155
Study 31340012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 30420289 — intervention group
Group type: EXPERIMENTAL
Intervention: LCB01-0371 400-1600 mg BID for 7 days
Number of subjects: 32
Study 30420289 — intervention group
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800 mg single oral dose
Number of subjects: 32
Study 30420289 — intervention group
Group type: EXPERIMENTAL
Intervention: LCB01-0371 400 mg tablet
Number of subjects: 32
Study 30420289 — intervention group
Group type: EXPERIMENTAL
Intervention: LCB01-0371
Number of subjects: 32
Study 27351713 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal drainage
Number of subjects: 414
Study 27351713 — intervention group
Group type: COMPARATOR
Intervention: No abdominal drainage
Number of subjects: 414
Study 25758845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth brushing
Number of subjects: 98
Study 25758845 — intervention group
Group type: EXPERIMENTAL
Intervention: Single tooth extraction
Number of subjects: 98
Study 25758845 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis (AP)
Number of subjects: 98
Study 23040973 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term growth hormone (GH) therapy
Number of subjects: 851
Study 23040973 — intervention group
Group type: COMPARATOR
Intervention: General population (control)
Number of subjects: 851
Study 20671099 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Number of subjects: 109
Study 20671099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercises
Number of subjects: 109
Study 20671099 — intervention group
Group type: COMPARATOR
Intervention: General exercises
Number of subjects: 109
Study 17954694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tigecycline (100 mg loading dose followed by 50 mg every 12 h or 50 mg loading dose followed by 25 mg every 12 h)
Number of subjects: 71
Study 17954694 — intervention group
Group type: COMPARATOR
Intervention: Cohort 4 (21 patients, 50 pathogens)
Number of subjects: 71
Study 17954694 — intervention group
Group type: COMPARATOR
Intervention: Cohort 5 (31 patients, 60 pathogens)
Number of subjects: 71
Study 16632821 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol/remifentanil)
Number of subjects: 22
Study 16632821 — intervention group
Group type: COMPARATOR
Intervention: SEVO (sevoflurane/remifentanil)
Number of subjects: 22
Study 12594143 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol
Number of subjects: 550
Study 12594143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 10810425 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 79
Study 10810425 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 8792790 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance interventions
Number of subjects: 630
Study 1473452 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 22
Study 1473452 — intervention group
Group type: COMPARATOR
Intervention: No acyclovir (Control)
Number of subjects: 22
Study 6365803 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg daily)
Number of subjects: 26
Study 6365803 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg daily)
Number of subjects: 26
Study 6365803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31898647 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐LD 25 mg/m2 and docetaxel 50 mg/m2
Number of subjects: 5
Study 31898647 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐LD 30 mg/m2 and docetaxel 50 mg/m2
Number of subjects: 5
Study 31898647 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐LD 30 mg/m2 and docetaxel 60 mg/m2
Number of subjects: 5
Study 31898647 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐LD and docetaxel regimen
Number of subjects: 5
Study 30675151 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (EG)
Number of subjects: 38
Study 30675151 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38
Study 27703344 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose (HD) of Fluticasone 1,000 μg/day
Number of subjects: 248
Study 23888466 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic mixture (neutral and acidic oligosaccharides)
Number of subjects: 93
Study 23888466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 22240800 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-pegylated liposomal doxorubicin (C-PLD)
Number of subjects: 976
Study 22240800 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (C-P)
Number of subjects: 976
Study 22240800 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 progression
Number of subjects: 976
Study 22240800 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 first progression
Number of subjects: 976
Study 22240800 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 or radiological first progression
Number of subjects: 976
Study 22240800 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic first progression
Number of subjects: 976
Study 20009095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 982
Study 20009095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 982
Study 20009095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 982
Study 18669966 — intervention group
Group type: EXPERIMENTAL
Intervention: Holland nail
Number of subjects: 190
Study 18669966 — intervention group
Group type: COMPARATOR
Intervention: DHS
Number of subjects: 190
Study 18669966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study 15933396 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal pain scale
Number of subjects: 160
Study 15933396 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal visual pain scale
Number of subjects: 160
Study 15933396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical visual pain scale
Number of subjects: 160
Study 15933396 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces pain scale
Number of subjects: 160
Study 15933396 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment scales (all four)
Number of subjects: 160
Study 15933396 — intervention group
Group type: COMPARATOR
Intervention: Observational pain rating scale
Number of subjects: 160
Study 12868184 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily for 30 days
Number of subjects: 35
Study 12868184 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg once daily for 30 days
Number of subjects: 35
Study 12868184 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 clinically healthy persons aged 21-54 years)
Number of subjects: 35
Study 10372724 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion (1.1 mg calcium gluconate/cc in 5% dextrose at a rate of 4 cc/kg x h) (n = 7)
Number of subjects: 16
Study 10372724 — intervention group
Group type: EXPERIMENTAL
Intervention: Human PTH-(1-34) infusion (0.55 U/kg x h) (n = 9)
Number of subjects: 16
Study 8501265 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen as protective therapy
Number of subjects: 39
Study 8501265 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 39
Study 3123603 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐deprenyl
Number of subjects: 0
Study 3123603 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 0
Study 29752998 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein group (HP) - 35 g of protein after training sessions
Number of subjects: 32
Study 29752998 — intervention group
Group type: COMPARATOR
Intervention: Low protein group (LP) - 35 g of placebo after training sessions
Number of subjects: 32
Study 29752998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 27758940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative computerized tomographic image‐guided endoscopic surgery
Number of subjects: 20
Study 27758940 — intervention group
Group type: COMPARATOR
Intervention: Medical control (MISTIE trial)
Number of subjects: 20
Study 26406063 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) at 25Hz for 4 weeks
Number of subjects: 20
Study 26406063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration) performing the same exercise as WBV group
Number of subjects: 20
Study 22691263 — intervention group
Group type: EXPERIMENTAL
Intervention: NOP‐47 (5 g)
Number of subjects: 21
Study 22691263 — intervention group
Group type: EXPERIMENTAL
Intervention: NOP‐47
Number of subjects: 21
Study 22691263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 21624138 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 40
Study 21624138 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 40
Study 19781472 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser (IntraLase, 30 or 60 kHz)
Number of subjects: 183
Study 19781472 — intervention group
Group type: COMPARATOR
Intervention: Mechanical microkeratome (Hansatome)
Number of subjects: 183
Study 16423671 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial contrast echocardiography (MCE)
Number of subjects: 50
Study 15239204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefitting hearing aid orientation (HAO) counseling
Number of subjects: 0
Study 15239204 — intervention group
Group type: EXPERIMENTAL
Intervention: Postfitting hearing aid orientation (HAO) counseling
Number of subjects: 0
Study 15239204 — intervention group
Group type: COMPARATOR
Intervention: No counseling
Number of subjects: 0
Study 11764222 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and education
Number of subjects: 600
Study 11764222 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 600
Study 11764222 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 600
Study 10093820 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with headache and CTS
Number of subjects: 32
Study 10093820 — intervention group
Group type: COMPARATOR
Intervention: Control group (52 sex- and age-matched children with headache without EEG abnormalities)
Number of subjects: 32
Study 7925334 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.167% alone
Number of subjects: 171
Study 7925334 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 2 micrograms ml‐1 (5 micrograms h‐1) in 0.167% bupivacaine
Number of subjects: 171
Study 7925334 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 4 micrograms ml‐1 (10 micrograms h‐1) in 0.167% bupivacaine
Number of subjects: 171
Study 7925334 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 4 micrograms ml‐1 (10 micrograms h‐1) in normal saline
Number of subjects: 171
Study 7925334 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil without bupivacaine
Number of subjects: 171
Study 7925334 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 5 micrograms h‐1
Number of subjects: 171
Study 2572412 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 94
Study 2572412 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 94
Study 2572412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 1190685 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intraperitoneal lavage with antibiotics
Number of subjects: 155
Study 1190685 — intervention group
Group type: COMPARATOR
Intervention: Postoperative drainage without lavage, systemic antibiotics
Number of subjects: 155
Study 31613172 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping + Balance Exercises (KT+BE)
Number of subjects: 44
Study 31613172 — intervention group
Group type: COMPARATOR
Intervention: Placebo Kinesio Taping + Balance Exercises (KTp+BE)
Number of subjects: 44
Study 31613172 — intervention group
Group type: COMPARATOR
Intervention: Kinesio Taping (KT) alone
Number of subjects: 44
Study 27168463 — intervention group
Group type: EXPERIMENTAL
Intervention: S-flurbiprofen plaster (SFPP)
Number of subjects: 633